Categories AlphaGraphs, Earnings, Finance

Infographic: Highlights of Morgan Stanley (MS) Q3 2022 earnings report

Banking giant Morgan Stanley (NYSE: MS) on Friday y reported lower earnings and revenues for the third quarter of 2022. The company’s stock dropped soon after the announcement.

Morgan Stanley Q3 2022 earnings infographic

Net income applicable to shareholders was $2.63 billion or $1.47 per share in the third quarter of 2022, compared to $3.71 billion or $1.98 per share in the same period a year ago.  Adjusted earnings dropped to $1.53 per share from $2.04 per share last year.

The bottom line was hurt by a 12% decrease in revenues to $12.9 billion. The company delivered ROTCE of 14.6%, or 15.2% excluding the impact of integration-related expenses.


Check this space to read management/analysts’ comments on Morgan Stanley’s Q3 2022 earnings


Shares of Morgan Stanley declined early Friday following the earnings announcement, after closing the last session higher.

Prior Performance

  • Morgan Stanley Q1 2022 earnings infographic
  • Morgan Stanley Q4 2021 earnings infographic
  • Morgan Stanley Q3 2021 earnings infographic

_________________________________________________________________________________________________________________

Stocks you may like:

Bank of America (BAC) Stock

Wells Fargo (WFC) Stock

JPMorgan Chase (JPM) Stock

Citigroup (C) Stock

Goldman Sachs (GS) Stock

Morgan Stanley (MS) Stock

_________________________________________________________________________________________________________________

Most Popular

Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report

Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,

J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights

The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was

Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials

Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top